Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 96

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 96
---
 other intellectual property rights alleging that our product candidates and/or proprietary technologies infringe their
intellectual property rights. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third
parties, exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand
and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights
of others. Moreover, it is not always clear to industry participants, including us, which patents cover various types of drugs, products
or their methods of use or manufacture. Thus, because of the large number of patents issued and patent applications filed in our fields,
there may be a risk that third parties allege they have patent rights encompassing our product candidates, technologies or methods.

Third parties may assert
that we are employing their proprietary technology without authorization. Generally, conducting preclinical and clinical trials and other
development activities in the United States is not considered an act of infringement. If CER-1236 or another product candidate is
cleared/approved by the FDA, a third party may then seek to enforce its patent by filing a patent infringement lawsuit against us. While
we do not believe that any patent claims that could have a materially adverse effect on the commercialization of our product candidates
are valid and enforceable, we may be incorrect in this belief, or we may not be able to prove it in litigation. In this regard, patents
issued in the United States by law enjoy a presumption of validity that can be rebutted only with evidence that is “clear
and convincing,” a heightened standard of proof. There may be issued third-party patents of which we are currently unaware with
claims to compositions, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product
candidates. Patent applications can take many years to issue. There may be currently pending patent applications which may later
result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim
that use of our technologies infringes upon these patents. Moreover, we may fail to identify relevant patents or incorrectly conclude
that a patent is invalid, not enforceable, exhausted, or not infringed by our activities. If any third-party patents were held by a court
of competent jurisdiction to cover the manufacturing process of our product candidates, constructs or molecules used in or formed during
the manufacturing process, or any final product itself,